Human Papillomavirus (HPV) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Human Papillomavirus (HPV) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Human Papillomavirus Vaccine Market

The global human papillomavirus vaccine market size was valued at USD 3.80 billion in 2019 and is projected to grow to USD 12.69 billion by 2027, exhibiting a CAGR of 16.3% during the forecast period of 2020-2027.

The current global COVID-19 pandemic greatly impacted the HPV Vaccine Market because of the shutdowns, disruptions in the supply chain, and diversion of attention to a new disease. Immunization applications through usual practice were lagging, and there was diminished intention toward vaccination, which controlled the human papillomavirus vaccine market growth.

The leading factors are a growing understanding of diseases caused by HPV, rising government responsibilities for vaccine distribution, rising incidence of cervical malignancies, and progress in vaccine technology.

Valent vaccines are a significant improvement in preventing the virus. As these vaccinations cover a more comprehensive range of HPV types, they offer a much better complete coverage against the HPV linked cancers which in turn is broadening the global human papillomavirus vaccine market share. The bound safety enhances and makes the immune reaction stronger and longer lasting, minimizing the risk of HPV diseases.

Comprehensive Analysis of Human Papillomavirus Vaccine Market

The market is divided into type, disorder indication, and distribution channels. Based on kind, polyvalent vaccines such as Gardasil and Gardasil 9 feature marketplace dominance due to their effectiveness in opposition to likened HPV trace and substantial revenue in Asia Pacific as well as in Europe and as compared with bivalent vaccines along with Cervarix that considerations weak income. On a door-by-door indication basis, HPV-related malignancies form the largest market, given high incidences and vaccination desires toward risky types such as HPV 16 and 18. Hospitals retain the most significant portion because of clean vaccine availability and retail pharmacy businesses, besides government providers who have a critical role in extending vaccine rights of entry in various parts of the world.

The North America region led the human papillomavirus vaccine market by benefitting a size of USD 1.83 billion in 2019 due to the higher sales price of Gardasil/Gardasil 9 and the rapid adoption of the Human Papillomavirus Vaccine throughout the location.

The leading players in the Human Papillomavirus Vaccine Market significantly influence its growth trajectory and set industry standards. These key players, including GlaxoSmithKline plc. (U.K., Europe) and Merck & Co., Inc. (New Jersey, U.S.), contribute to a competitive landscape, driving innovation and advancements in vaccine development and distribution. Their efforts play a crucial role in addressing global demand and expanding access to HPV vaccines.

In July 2020, Merck introduced that the USFDA has granted popularity of an improved indication of GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) to prevent oropharyngeal and different head and neck cancers caused by HPV kinds sixteen, 18, 31, 33, forty five, fifty two, and fifty eight.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationBy Type

Bivalent

Polyvalent

By Disease Indication

HPV Related Cancer

Gential Warts

By Distribution Channel

Hospital & Retail Pharmacies

Government Suppliers

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.